Mikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, Muthiah Vaduganathan, Ian J Kulac, Carolyn S P Lam, Adrian F Hernandez, Felipe A Martinez, Silvio E Inzucchi, Sanjiv J Shah, Rudolf A de Boer, Pardeep S Jhund, Akshay S Desai, James C Fang, Yaling Han, Josep Comin-Colet, Orly Vardeny, Daniel Lindholm, Ulrica Wilderäng, Olof Bengtsson, John J V McMurray, Scott D Solomon
BACKGROUND: Patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden of symptoms, physical limitations, and poor quality of life; improving health status is a key goal of management. OBJECTIVES: In a prespecified analysis of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial, we examine effects of dapagliflozin on health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ)...
February 7, 2023: Journal of the American College of Cardiology